MX2017001038A - Variantes de proteina de unión al factor h y metodos de uso de estas. - Google Patents

Variantes de proteina de unión al factor h y metodos de uso de estas.

Info

Publication number
MX2017001038A
MX2017001038A MX2017001038A MX2017001038A MX2017001038A MX 2017001038 A MX2017001038 A MX 2017001038A MX 2017001038 A MX2017001038 A MX 2017001038A MX 2017001038 A MX2017001038 A MX 2017001038A MX 2017001038 A MX2017001038 A MX 2017001038A
Authority
MX
Mexico
Prior art keywords
methods
factor
binding protein
protein variants
proteins
Prior art date
Application number
MX2017001038A
Other languages
English (en)
Inventor
T Beernink Peter
Original Assignee
Childrens Hospital & Res Center At Oakland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital & Res Center At Oakland filed Critical Childrens Hospital & Res Center At Oakland
Publication of MX2017001038A publication Critical patent/MX2017001038A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se brindan proteínas variantes de unión al factor H que pueden provocar anticuerpos bactericidas para al menos una cepa de Neisseria meningitidis, composiciones que comprenden dichas proteínas y métodos de uso de dichas proteínas.
MX2017001038A 2014-07-23 2015-07-22 Variantes de proteina de unión al factor h y metodos de uso de estas. MX2017001038A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462028123P 2014-07-23 2014-07-23
PCT/US2015/041616 WO2016014719A1 (en) 2014-07-23 2015-07-22 Factor h binding protein variants and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2017001038A true MX2017001038A (es) 2018-02-09

Family

ID=55163727

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017001038A MX2017001038A (es) 2014-07-23 2015-07-22 Variantes de proteina de unión al factor h y metodos de uso de estas.
MX2021005373A MX2021005373A (es) 2014-07-23 2017-01-23 Variantes de proteinas de union al factor h y metodos de uso de estas.
MX2023000204A MX2023000204A (es) 2014-07-23 2017-01-23 Variantes de proteinas de union al factor h y metodos de uso de estas.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2021005373A MX2021005373A (es) 2014-07-23 2017-01-23 Variantes de proteinas de union al factor h y metodos de uso de estas.
MX2023000204A MX2023000204A (es) 2014-07-23 2017-01-23 Variantes de proteinas de union al factor h y metodos de uso de estas.

Country Status (15)

Country Link
US (8) US10266572B2 (es)
EP (2) EP4074726A3 (es)
JP (3) JP6796057B2 (es)
KR (2) KR20170028442A (es)
CN (2) CN106715464B (es)
AU (4) AU2015292615B2 (es)
BR (1) BR112017001417B1 (es)
CA (2) CA3212723A1 (es)
CO (1) CO2017000558A2 (es)
CR (1) CR20170020A (es)
ES (1) ES2922554T3 (es)
MX (3) MX2017001038A (es)
NZ (4) NZ766444A (es)
RU (1) RU2714248C2 (es)
WO (1) WO2016014719A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011126863A1 (en) 2010-03-30 2011-10-13 Children's Hospital & Research Center Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
NZ766444A (en) 2014-07-23 2024-01-26 Children’S Hospital & Res Center At Oakland Factor h binding protein variants and methods of use thereof
KR101855139B1 (ko) 2016-11-16 2018-05-08 주식회사 케이엠더블유 Mimo 안테나에서의 캘리브레이션
WO2018093176A2 (ko) 2016-11-16 2018-05-24 주식회사 케이엠더블유 적층구조의 mimo 안테나 어셈블리
BR112020011019A2 (pt) * 2017-12-04 2020-11-17 De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport processo aprimorado para produzir vesículas de membrana externa
EP3607967A1 (en) * 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
GB202016604D0 (en) 2020-10-20 2020-12-02 Univ Of Oxford Compositions and methods for inducing an immune response
JP2024507828A (ja) 2021-02-19 2024-02-21 サノフィ パスツール インコーポレイテッド Ｂ群髄膜炎菌組換えワクチン
WO2024030931A1 (en) 2022-08-03 2024-02-08 Sanofi Pasteur Inc. Adjuvanted immunogenic composition against neisseria meningitidis b

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
PL170980B1 (pl) 1992-06-25 1997-02-28 Smithkline Beecham Biolog Szczepionka PL PL PL PL PL PL PL
ES2162139T5 (es) 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
DE69838294T2 (de) 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
ES2298316T3 (es) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
EP2261343A3 (en) 1998-05-01 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
US20070026021A1 (en) 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
EP1126876B1 (en) 1998-10-16 2007-03-21 GlaxoSmithKline Biologicals S.A. Adjuvant systems and vaccines
MY125202A (en) 1999-03-19 2006-07-31 Smithkline Beecham Biologicals S A Vaccine
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
EP1221971A2 (en) 1999-09-24 2002-07-17 SmithKline Beecham Biologics SA Use of the combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
CZ20021045A3 (cs) 1999-09-24 2002-08-14 Smithkline Beecham Biologicals S. A. Pomocný prostředek
WO2001034642A2 (en) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Control of neisserial membrane synthesis
AU2013206190A1 (en) 1999-11-29 2013-06-27 Novartis Vaccines And Diagnostics S.R.L. Compositions comprising Neisseria meningitidis antigens from serogroups B and C as well as a further antigen
DK2289545T3 (en) 2000-01-17 2016-09-05 Glaxosmithkline Biologicals Sa Supplemented OMV vaccine against meningococcus
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
US6839862B2 (en) 2001-05-31 2005-01-04 Koninklijke Philips Electronics N.V. Parallel data communication having skew intolerant data groups
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
AU2003274511B2 (en) 2002-10-11 2009-06-04 Glaxosmithkline Biologicals S.A. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP1706481A2 (en) 2003-12-23 2006-10-04 GlaxoSmithKline Biologicals S.A. Vaccine
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
CA2590974C (en) 2005-01-27 2017-10-03 Children's Hospital & Research Center At Oakland Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
EP2185576A4 (en) 2007-08-02 2011-01-12 Childrens Hosp & Res Ct Oak FHBP- AND LPXL1-BASED VESICIUM VACCINES FOR BROADBAND PROTECTION AGAINST NEISSERIA MENINGITIDIS-RELATED DISEASES
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
EP2265640B1 (en) 2008-03-10 2015-11-04 Children's Hospital & Research Center at Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
CN102203276A (zh) * 2008-08-27 2011-09-28 奥克兰儿童医院及研究中心 基于补体因子h对脑膜炎奈瑟球菌血清杀菌活性的鉴定
WO2010028096A2 (en) 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presenting an epitope of an a domain of factor h binding protein and methods of use
IT1394288B1 (it) 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic Immunogeni di proteine che legano il fattore h.
GB0819633D0 (en) 2008-10-25 2008-12-03 Isis Innovation Composition
PL2411048T3 (pl) 2009-03-24 2020-11-16 Glaxosmithkline Biologicals Sa Adjuwantowe meningokokowe białko wiążące czynnik h
EP2424563A4 (en) 2009-04-30 2013-10-30 Childrens Hosp & Res Ct Oak CHIMERIC FACTOR H-BINDING PROTEINS AND METHOD OF USE THEREOF
JP5960055B2 (ja) * 2009-10-27 2016-08-02 ノバルティス アーゲー 改変髄膜炎菌ｆＨＢＰポリペプチド
WO2011126863A1 (en) * 2010-03-30 2011-10-13 Children's Hospital & Research Center Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
JP6002763B2 (ja) 2011-07-07 2016-10-05 デ スタート デル ネダーランデン、フェルト．ドール デ ミニスター ファン フェーウェーエス グラム陰性細菌の外膜小胞を、洗浄剤を含まずに生産するためのプロセス
WO2013078223A1 (en) 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
KR101763625B1 (ko) * 2012-03-09 2017-08-01 화이자 인코포레이티드 수막염균 조성물 및 이의 사용 방법
GB201215005D0 (en) 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
EP3782643A1 (en) 2014-02-28 2021-02-24 GlaxoSmithKline Biologicals SA Modified meningococcal fhbp polypeptides
CN104072590B (zh) * 2014-06-24 2017-08-25 上海生物制品研究所有限责任公司 一种脑膜炎球菌抗原组合及其应用
EA201692552A1 (ru) * 2014-07-17 2017-06-30 Глаксосмитклайн Байолоджикалс С.А. МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
NZ766444A (en) * 2014-07-23 2024-01-26 Children’S Hospital & Res Center At Oakland Factor h binding protein variants and methods of use thereof
EP3607967A1 (en) * 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides

Also Published As

Publication number Publication date
US10266572B2 (en) 2019-04-23
EP3172224B1 (en) 2022-06-29
RU2020105192A (ru) 2020-02-12
US11834476B2 (en) 2023-12-05
CN106715464B (zh) 2021-03-16
AU2019264600A1 (en) 2019-12-05
KR20170028442A (ko) 2017-03-13
RU2017104742A (ru) 2018-08-29
US10995122B2 (en) 2021-05-04
BR112017001417B1 (pt) 2023-11-07
KR20230155595A (ko) 2023-11-10
AU2021203828B2 (en) 2023-04-13
JP6796057B2 (ja) 2020-12-02
US20210340191A1 (en) 2021-11-04
JP2017522877A (ja) 2017-08-17
US10836799B2 (en) 2020-11-17
EP3172224A1 (en) 2017-05-31
AU2023204391A1 (en) 2023-08-03
BR112017001417A2 (pt) 2017-11-21
CN106715464A (zh) 2017-05-24
AU2015292615B2 (en) 2019-10-24
AU2015292615A1 (en) 2017-03-16
US20190225655A1 (en) 2019-07-25
CO2017000558A2 (es) 2017-06-20
NZ766005A (en) 2024-03-22
US20170183384A1 (en) 2017-06-29
US20240101610A1 (en) 2024-03-28
AU2019264600B2 (en) 2021-04-01
AU2021203828A1 (en) 2021-07-08
RU2714248C2 (ru) 2020-02-13
CR20170020A (es) 2017-08-10
JP2021000121A (ja) 2021-01-07
CN112851768A (zh) 2021-05-28
US20240025951A1 (en) 2024-01-25
NZ729206A (en) 2022-07-01
MX2021005373A (es) 2021-07-06
US20200095288A1 (en) 2020-03-26
US11673920B2 (en) 2023-06-13
US10487122B2 (en) 2019-11-26
JP7221917B2 (ja) 2023-02-14
NZ766444A (en) 2024-01-26
MX2023000204A (es) 2023-02-09
CA2955802C (en) 2023-10-31
WO2016014719A1 (en) 2016-01-28
EP4074726A3 (en) 2022-11-23
US20200109179A1 (en) 2020-04-09
NZ766003A (en) 2024-01-26
ES2922554T3 (es) 2022-09-16
JP2023011916A (ja) 2023-01-24
US20210101942A1 (en) 2021-04-08
EP3172224A4 (en) 2018-04-18
CA3212723A1 (en) 2016-01-28
CA2955802A1 (en) 2016-01-28
RU2017104742A3 (es) 2019-02-27
EP4074726A2 (en) 2022-10-19

Similar Documents

Publication Publication Date Title
PH12016501644B1 (en) Binding proteins and methods of use thereof
MX2021005373A (es) Variantes de proteinas de union al factor h y metodos de uso de estas.
PH12017502180A1 (en) Tau-binding antibodies
MX2022003891A (es) Anticuerpos anti-muc16 y sus usos.
IL276715A (en) Preparations and methods for administration of membrane protein
EP3256495A4 (en) Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
MX2018011503A (es) Proteinas de union y metodos de uso de las mismas.
NZ727020A (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
PH12017502207A1 (en) Tau-binding antibodies
EP4249515A3 (en) Humanized or chimeric cd3 antibodies
MX2019007554A (es) Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso.
MX2023008211A (es) Composiciones y metodos para disminuir la expresion de tau.
MX2017000775A (es) Vacunas de meningococos.
IL265831A (en) Preparations and methods for protein expression and administration
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
MX2017007747A (es) Anticuerpos para il-17c.
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis